BRPI0519141A2 - processo para e intermediÁrios na preparaÇço de canfosfamida e dos sais das mesmas, composiÇÕes farmacÊuticas contendo alguns intermediÁrios e o uso do mesmo como agentes anticÂncer - Google Patents

processo para e intermediÁrios na preparaÇço de canfosfamida e dos sais das mesmas, composiÇÕes farmacÊuticas contendo alguns intermediÁrios e o uso do mesmo como agentes anticÂncer

Info

Publication number
BRPI0519141A2
BRPI0519141A2 BRPI0519141-6A BRPI0519141A BRPI0519141A2 BR PI0519141 A2 BRPI0519141 A2 BR PI0519141A2 BR PI0519141 A BRPI0519141 A BR PI0519141A BR PI0519141 A2 BRPI0519141 A2 BR PI0519141A2
Authority
BR
Brazil
Prior art keywords
intermediates
salts
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
BRPI0519141-6A
Other languages
English (en)
Inventor
William A Boulanger
Steven J Collier
Stephen A Eastham
Dennis L Edie
Ronan Y Guevel
Pedro E Hernandez Abad
Jason R Herr
Hans J Kjaersgaard
Harold Meckler
Robert E Polomski
Steven R Schow
Pavel E Zhichkin
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Publication of BRPI0519141A2 publication Critical patent/BRPI0519141A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/36Amides thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2404Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/24Esteramides
    • C07F9/2454Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/22Amides of acids of phosphorus
    • C07F9/26Amides of acids of phosphorus containing P-halide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/44Amides thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

PROCESSO PARA E INTERMEDIÁRIOS NA PREPARAÇçO DE CANFOSFAMIDA E DOS SAIS DAS MESMAS, COMPOSIÇÕES FARMACÊUTICAS CONTENDO ALGUNS INTERMEDIÁRIOS E O USO DO MESMO COMO AGENTES ANTICANCER. A presente invenção refere-se a um processo para, e intermediários na preparação de canfosfamida e os sais das mesmas, composições farmacêuticas contendo alguns intermediários e o uso dos mesmos como agentes anticâncer.
BRPI0519141-6A 2004-12-21 2005-11-23 processo para e intermediÁrios na preparaÇço de canfosfamida e dos sais das mesmas, composiÇÕes farmacÊuticas contendo alguns intermediÁrios e o uso do mesmo como agentes anticÂncer BRPI0519141A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/018,391 US8198247B2 (en) 2004-12-21 2004-12-21 Process for and intermediates in the preparation of canfosfamide and its salts
PCT/US2005/042693 WO2006068769A1 (en) 2004-12-21 2005-11-23 Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents

Publications (1)

Publication Number Publication Date
BRPI0519141A2 true BRPI0519141A2 (pt) 2008-12-30

Family

ID=36216909

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519141-6A BRPI0519141A2 (pt) 2004-12-21 2005-11-23 processo para e intermediÁrios na preparaÇço de canfosfamida e dos sais das mesmas, composiÇÕes farmacÊuticas contendo alguns intermediÁrios e o uso do mesmo como agentes anticÂncer

Country Status (15)

Country Link
US (2) US8198247B2 (pt)
EP (1) EP1827605B1 (pt)
JP (1) JP5060306B2 (pt)
KR (1) KR20070089795A (pt)
CN (1) CN101080251B (pt)
AR (1) AR052167A1 (pt)
AU (1) AU2005319579B2 (pt)
BR (1) BRPI0519141A2 (pt)
CA (1) CA2587088A1 (pt)
EA (1) EA016052B1 (pt)
IL (1) IL182835A0 (pt)
MX (1) MX2007007215A (pt)
TW (1) TW200633717A (pt)
WO (1) WO2006068769A1 (pt)
ZA (1) ZA200704318B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4521488B2 (ja) * 2008-08-21 2010-08-11 福美 森重 線維筋痛症候群の治療剤並びに筋攣縮による疼痛の治療剤
US8324426B2 (en) 2008-08-28 2012-12-04 Telik, Inc. Formulations of canfosfamide and their preparation
US20100056825A1 (en) * 2008-08-28 2010-03-04 Telik, Inc. Formulations of canfosfamide and their preparation
CA2733732A1 (en) * 2011-02-25 2012-08-25 Telik, Inc. Formulations of canfosfamide and their preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556942A (en) * 1991-04-29 1996-09-17 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
EP1072608B1 (en) * 1998-04-16 2005-06-15 Teijin Limited Glutathione derivatives and dosage forms thereof
US6417397B1 (en) * 1999-10-04 2002-07-09 The Regents Of The University Of California, San Diego N-substituted alkylamino acids for use as amino-protecting groups
UA74574C2 (en) 2000-05-02 2006-01-16 Telik Inc Bis (n,n'-bis(2-halogenethyl)amino)phosphodiamates, a method for producing thereof (variants), a pharmaceutical composition containing them, and a method for the treatment of tumors
US6506739B1 (en) * 2001-05-01 2003-01-14 Telik, Inc. Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents
KR101244609B1 (ko) * 2005-01-06 2013-03-25 텔리크 인코포레이티드 트리펩티드 및 테트라펩티드 티오에테르

Also Published As

Publication number Publication date
CN101080251B (zh) 2012-08-29
US20060135409A1 (en) 2006-06-22
EP1827605A1 (en) 2007-09-05
MX2007007215A (es) 2007-08-14
US20120238772A1 (en) 2012-09-20
IL182835A0 (en) 2007-08-19
AU2005319579B2 (en) 2011-07-21
WO2006068769A1 (en) 2006-06-29
EA200701180A1 (ru) 2008-04-28
CN101080251A (zh) 2007-11-28
US8334266B2 (en) 2012-12-18
US8198247B2 (en) 2012-06-12
AU2005319579A1 (en) 2006-06-29
EP1827605B1 (en) 2014-03-26
AR052167A1 (es) 2007-03-07
CA2587088A1 (en) 2006-06-29
TW200633717A (en) 2006-10-01
EA016052B1 (ru) 2012-01-30
ZA200704318B (en) 2008-09-25
JP2008524327A (ja) 2008-07-10
KR20070089795A (ko) 2007-09-03
JP5060306B2 (ja) 2012-10-31

Similar Documents

Publication Publication Date Title
BRPI0712631A8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
BR112014007193A2 (pt) derivados de pirazoloquinolinona, preparação dos mesmos e uso terapêutico dos mesmos
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
BRPI0509655A (pt) uso de derivados de 9h-purina-2,6-diamina no tratamento de doenças proliferativas e novos derivados de 9h-purina-2,6-diamina
CR11857A (es) Compuestos pirazolicos 436
GT200600144A (es) 1h-quinazolin-2,4-dionas
BRPI0508540A8 (pt) Composto, composição farmacêutica, e, uso de um composto
CR11623A (es) Compuestos
BR112012011793A2 (pt) "acrilamidas heterocíclicas e seu uso como farmacêuticos"
BRPI0813237B8 (pt) composto, método para preparar o composto, medicamento, e, uso do composto
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
BRPI0513819A (pt) inibidores de hsp90
ECSP088884A (es) Compuestos heterociclicos fusionados y su uso como moduladores de mglur5
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
BRPI0817597A2 (pt) Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos
DOP2013000130A (es) Compuestos de pirimidinona para uso en el tratamiento de las enfermedades o condiciones mediada por lp - pla2
BR112014014452A2 (pt) derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos
UY29818A1 (es) Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos
BRPI0916069C1 (pt) composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição
BRPI0515918B8 (pt) sais de composto heterocíclico de ligação à quimiocina, seu processo de preparação e composição farmacêutica que os compreende
BR112013032766A2 (pt) "compostos de ligação com catepsina, composto que visa catepsina, processo para a preparação dos referidos compostos e usos dos mesmos na preparação de medicamentos
BR112012012261A2 (pt) compostos como moduladores de receptor com utilidade terapêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2281 DE 23/09/2014.